JP2024530152A5 - - Google Patents
Info
- Publication number
- JP2024530152A5 JP2024530152A5 JP2024506201A JP2024506201A JP2024530152A5 JP 2024530152 A5 JP2024530152 A5 JP 2024530152A5 JP 2024506201 A JP2024506201 A JP 2024506201A JP 2024506201 A JP2024506201 A JP 2024506201A JP 2024530152 A5 JP2024530152 A5 JP 2024530152A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- unit dosage
- region
- variant
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203856P | 2021-08-02 | 2021-08-02 | |
| US63/203,856 | 2021-08-02 | ||
| PCT/IB2022/000443 WO2023012515A2 (en) | 2021-08-02 | 2022-08-02 | Subcutaneous unit dosage forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024530152A JP2024530152A (ja) | 2024-08-16 |
| JP2024530152A5 true JP2024530152A5 (https=) | 2025-08-13 |
Family
ID=83192179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506201A Pending JP2024530152A (ja) | 2021-08-02 | 2022-08-02 | 皮下単位剤形 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240325528A1 (https=) |
| EP (1) | EP4380618A2 (https=) |
| JP (1) | JP2024530152A (https=) |
| KR (1) | KR20240040104A (https=) |
| CN (1) | CN117897172A (https=) |
| AU (1) | AU2022322077A1 (https=) |
| CA (1) | CA3228105A1 (https=) |
| IL (1) | IL310608A (https=) |
| MX (1) | MX2024001631A (https=) |
| TW (1) | TW202320849A (https=) |
| WO (1) | WO2023012515A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3081144A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| JP2023509195A (ja) | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
| CN119365209A (zh) * | 2022-04-26 | 2025-01-24 | 阿根思有限公司 | 用于使用fcrn拮抗剂治疗大疱性类天疱疮的方法 |
| CN119698429A (zh) | 2022-06-15 | 2025-03-25 | 阿根思有限公司 | Fcrn结合分子及使用方法 |
| WO2025233684A1 (en) * | 2024-05-10 | 2025-11-13 | argenx BV | Subcutaneous formulations, pre-filled syringes and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| SI4269578T1 (sl) | 2008-03-06 | 2024-07-31 | Halozyme, Inc. | Sestava topne hialuronidaze |
| EA022752B1 (ru) | 2008-12-09 | 2016-02-29 | Галозим, Инк. | Длинные растворимые полипептиды рн20 и их использование |
| HUE028832T2 (en) * | 2009-09-17 | 2017-01-30 | Baxalta Inc | Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation |
| WO2013102144A2 (en) | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
| CA3081144A1 (en) * | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| MX2020009824A (es) | 2018-07-25 | 2021-01-15 | Alteogen Inc | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. |
| KR102650991B1 (ko) | 2019-03-25 | 2024-03-27 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
| JP2023509195A (ja) * | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
-
2022
- 2022-08-02 KR KR1020247006620A patent/KR20240040104A/ko active Pending
- 2022-08-02 JP JP2024506201A patent/JP2024530152A/ja active Pending
- 2022-08-02 WO PCT/IB2022/000443 patent/WO2023012515A2/en not_active Ceased
- 2022-08-02 MX MX2024001631A patent/MX2024001631A/es unknown
- 2022-08-02 EP EP22764840.9A patent/EP4380618A2/en active Pending
- 2022-08-02 AU AU2022322077A patent/AU2022322077A1/en active Pending
- 2022-08-02 TW TW111128959A patent/TW202320849A/zh unknown
- 2022-08-02 CN CN202280059734.XA patent/CN117897172A/zh active Pending
- 2022-08-02 IL IL310608A patent/IL310608A/en unknown
- 2022-08-02 CA CA3228105A patent/CA3228105A1/en active Pending
-
2024
- 2024-02-02 US US18/431,585 patent/US20240325528A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024530152A5 (https=) | ||
| JP2018509413A5 (https=) | ||
| US20240287187A1 (en) | Bispecific antibody | |
| JP6225142B2 (ja) | 規則的に多量体化された免疫グロブリンＦｃ組成物を作製するための天然ヒトタンパク質断片の融合タンパク質 | |
| JP7476997B2 (ja) | 二重特異性抗体 | |
| CA3067584A1 (en) | Anti-bcma heavy chain-only antibodies | |
| CN106795220A (zh) | 通过αβTCR结合多肽的多重施用的用于增强免疫抑制疗法的方法 | |
| CA3258002A1 (en) | FCRN BINDING MOLECULES AND METHODS OF USE | |
| CA3065951A1 (en) | Anti-bcma heavy chain-only antibodies | |
| JP2025504815A5 (https=) | ||
| US20250368736A1 (en) | Bispecific antibody | |
| JP2022536486A5 (https=) | ||
| JP2003519619A (ja) | 免疫修飾活性を有する新規Ｉｇ断片 | |
| JP7574692B2 (ja) | 二重特異性抗体 | |
| US20190330313A1 (en) | Method for increasing binding affinity of igg-like antibody to fcrn and prolonging serum half-life thereof | |
| JP7714992B2 (ja) | 二重特異性抗体を有効成分として含む医薬組成物 | |
| RU2814713C2 (ru) | Биспецифическое антитело | |
| JP2025512483A (ja) | 抗体を選択的に排除するための分子の新規のクラス | |
| RU2796019C2 (ru) | Биспецифическое антитело | |
| NZ734416A (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| NZ773089B2 (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| NZ773089A (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| HK40036202A (en) | Bispecific antibody |